CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has initiated a Phase III clinical study for its Category 1 drug JMT101. This study combines JMT101 with osimertinib (Tagrisso) and compares it against osimertinib alone in the first-line treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-squamous non-small cell lung cancer (NSCLC). JMT101, an anti-EGFR monoclonal antibody (mAb), marks a significant milestone as the first drug of its kind in China to enter Phase III studies for NSCLC.
Known for its high affinity and efficacy, JMT101 demonstrates significantly lower immunogenicity and side effects compared to similar products on the market. This new development is expected to enhance treatment options for patients battling EGFR mutation-positive NSCLC, offering a potential new standard of care.- Flcube.com
